New HCV Peer-Reviewed PDFs For Free!
Posted on October 16, 2015
For one month only! HCV Peer-Reviewed PDF Bonanza!!!
To satisfy your educational needs, Elsevier Multimedia Publishing has made available another 18 new, peer-reviewed, full text articles for free! Please see below for a list of these articles, which can readily be accessed in our American Journal of Medicine Hepatitis C Resource Center (hepcresource.amjmed.com).
Note that these free, full text HCV peer-reviewed articles will be removed from the Resource Center in one month!
The AJM Hepatitis C Resource Center provides both primary care providers and specialists with continually updated treatment guidelines, and an up-to-date repository of informative, freely-available, full-text articles to encourage effective HCV screening and diagnosis, and to highlight the promise of novel treatment regimens.
Free HCV Peer-Reviewed PDF Bonanza!!! New peer-reviewed, full-text article in the section of our Resource Center focused toward Primary Care Providers
Please visit the American Journal of Medicine Hepatitis Resource Center (hepcresource.amjmed.com) to access the free full-text articles.
Hepatitis C: An Introduction for Primary Care Providers
Prevalence and Management of Chronic Hepatitis C Virus Infection in Women.
Beste LA, Bondurant HC, Ioannou GN.
Med Clin North Am. 2015 May;99(3):575-86. doi: 10.1016/j.mcna.2015.01.009. Epub 2015 Feb 28.
PMID: 25841601
Hepatitis C virus seroprevalence in the general female population from 8 countries.
Quesada P, Whitby D, Benavente Y, Miley W, Labo N, Chichareon S, Trong N, Shin HR, Anh PT, Thomas J, Matos E, Herrero R, Muñoz N, Molano M, Franceschi S, de Sanjosé S.
J Clin Virol. 2015 Jul;68:89-93. doi: 10.1016/j.jcv.2015.05.005. Epub 2015 May 12.
PMID: 26071344
Suboptimal Surveillance for and Knowledge of Hepatocellular Carcinoma Among Primary Care Providers.
McGowan CE, Edwards TP, Luong MU, Hayashi PH.
Clin Gastroenterol Hepatol. 2015 Apr;13(4):799-804. doi: 10.1016/j.cgh.2014.07.056. Epub 2014 Aug 10.
PMID: 25117773
Screening and Diagnosis of Hepatitis C
Evaluation of viral load in saliva from patients with chronic hepatitis C infection.
Xavier Santos RL, de Deus DM, de Almeida Lopes EP, Duarte Coêlho MR, de Castro JF.
J Infect Public Health. 2015 Sep-Oct;8(5):474-80. doi: 10.1016/j.jiph.2015.04.025. Epub 2015 Jun 2.
PMID: 26044945
On-chip purification and detection of hepatitis C virus RNA from human plasma.
Vaghi V, Potrich C, Pasquardini L, Lunelli L, Vanzetti L, Ebranati E, Lai A, Zehender G, Mombello D, Cocuzza M, Pirri CF, Pederzolli C.
Biophys Chem. 2015 Jun 11. pii: S0301-4622(15)30009-0. doi: 10.1016/j.bpc.2015.06.005. [Epub ahead of print].
PMID: 26091724
The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: A systematic review of the literature.
Coats JT, Dillon JF.
Int J Drug Policy. 2015 Jun 4. pii: S0955-3959(15)00134-6. doi: 10.1016/j.drugpo.2015.05.001. [Epub ahead of print]
PMID: 26118799
Hepatitis C Treatment and Management in Real World Settings
Effect of Gender on the Response to Hepatitis C Treatment in an Inner-City Population.
Simoes P, Asaad A, Abed J, Engelson ES, Kotler DP.
Womens Health Issues. 2015 May-Jun;25(3):289-93. doi: 10.1016/j.whi.2015.02.008.
PMID: 25965157
Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
Alavi M, Spelman T, Matthews GV, Haber PS, Day C, van Beek I, Walsh N, Yeung B, Bruneau J, Petoumenos K, Dolan K, Kaldor JM, Dore GJ, Hellard M, Grebely J; ATAHC Study Group.
Int J Drug Policy. 2015 May 21. pii: S0955-3959(15)00136-X. doi: 10.1016/j.drugpo.2015.05.003. [Epub ahead of print]
PMID: 26115881
The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study.
Fortier E, Alavi M, Micallef M, Dunlop AJ, Balcomb AC, Day CA, Treloar C, Bath N, Haber PS, Dore GJ, Bruneau J, Grebely J; ETHOS Study Group.
Int J Drug Policy. 2015 Jun 11. pii: S0955-3959(15)00181-4. doi: 10.1016/j.drugpo.2015.06.001. [Epub ahead of print]
PMID: 26145482
Free HCV Peer-Reviewed PDF Bonanza!!! New peer-reviewed, full-text articles in the section of the Resource Center focused toward Hepatologists, Gastroenterologists & Infectious Disease Specialists
Please visit the American Journal of Medicine Hepatitis C Resource Center (hepcresource.amjmed.com) to access the free full-text articles.
Hepatitis C: Clinical Scenarios and Therapeutic Overview
Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.
Meyer JP, Moghimi Y, Marcus R, Lim JK, Litwin AH, Altice FL.
Int J Drug Policy. 2015 May 17. pii: S0955-3959(15)00135-8. doi: 10.1016/j.drugpo.2015.05.002. [Epub ahead of print]
PMID: 26077144
Gender differences in planning ability and hepatitis C virus among people who inject drugs.
Scheidell JD, Khan MR, Clifford LM, Dunne EM, Keen LD 2nd, Latimer WW.
Addict Behav. 2015 Aug;47:33-7. doi: 10.1016/j.addbeh.2015.03.019. Epub 2015 Mar 26.
PMID: 25863005
Modeling the effect of HIV coinfection on clearance and sustained virologic response during treatment for hepatitis C virus.
Birgera R, Kouyosb R, Dushoff J, Grenfella B.
Epidemics. 2015;12:1-10.
Genetics, Polymorphisms, and Treatment Resistance
Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development.
Welsch C.
Drug Discov Today Technol. 2014 Mar;11:19-25. doi: 10.1016/j.ddtec.2013.12.003.
PMID: 24847649
Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease.
Nagpal N, Goyal S, Wahi D, Jain R, Jamal S, Singh A, Rana P, Grover A.
Gene. 2015 Oct 1;570(1):115-21. doi: 10.1016/j.gene.2015.06.008. Epub 2015 Jun 6.
PMID: 26055089
Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure.
Macartney MJ, Irish D, Bridge SH, Garcia-Diaz A, Booth CL, McCormick AL, Labbett W, Smith C, Velazquez C, Tanwar S, Trembling P, Jacobs M, Dusheiko G, Rosenberg W, Haque T.
Antiviral Res. 2014 May;105:112-7. doi: 10.1016/j.antiviral.2014.02.019. Epub 2014 Mar 1.
PMID: 24594347
Hepatitis C Clinical Trials
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.
Khalaf N, White D, Kanwal F, Ramsey D, Mittal S, Tavakoli-Tabasi S, Kuzniarek J, El-Serag HB.
Clin Gastroenterol Hepatol. 2015 Aug;13(8):1521-1531.e3. doi: 10.1016/j.cgh.2015.01.030. Epub 2015 Mar 14.
PMID: 25777972
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.
Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, Silk R, Kotb C, Gross C, Teferi G, Sugarman K, Pang PS, Osinusi A, Polis MA, Rustgi V, Masur H, Kottilil S.
Lancet Infect Dis. 2015 Sep;15(9):1049-54. doi: 10.1016/S1473-3099(15)00157-7. Epub 2015 Jul 14.
PMID: 26187031
Ledipasvir-sofosbuvir for hepatitis C genotype 4 infection.
Smith MA, Mohammad RA.
Lancet Infect Dis. 2015 Sep;15(9):993-5. doi: 10.1016/S1473-3099(15)00223-6. Epub 2015 Jul 14.
PMID: 26187029
Join the discussion